BioCentury
ARTICLE | Finance

Ebb & Flow

January 28, 2002 8:00 AM UTC

ImClone's fall appeared to hit a sordid bottom on Thursday with a "tell-all" story in The New York Timesthat ventured into the personal lives of the company's management. But IMCL filed several 8-Ks on Friday that quickly made bird cage liner of the Timesarticle.

Friday's news included disclosure of emergency stock sales to meet executive margin calls; the resignation of an IMCL board member; and the fact that the SEC and Justice Department are inquiring into the company's handling of its Erbitux trials and BLA submission...